Line 23: | Line 23: | ||
In the section of <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Attributions">attribution</a>, we described all the help we have acknowledged. </li> | In the section of <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Attributions">attribution</a>, we described all the help we have acknowledged. </li> | ||
<li><b>Document at least one new standard BioBrick Part or Device central to your project and submit this part to the iGEM Registry. </b><br> | <li><b>Document at least one new standard BioBrick Part or Device central to your project and submit this part to the iGEM Registry. </b><br> | ||
− | + | <a target="blank" href="http://parts.igem.org/Part:BBa_K2018030">K2018030</a> is a secretion system for poly-beta-hydroxybutyrate (PHB). This secretion tags PHB with a hybrid protein consisting of phasin, a protein that binds PHB, and a hemolysin tag, that is recognised by a type 2 secretion system. The biobrick also contains two transport proteins that will recognize the hybrid protein, and secrete it along with PHB. This construct generates an enormous increase in PHB yield, and creates the possibility for a large scale continous production of PHB in a fed batch.<br> </li> | |
</ul><hr> | </ul><hr> | ||
<h5><b>Silver 3/3</b></h5><hr> | <h5><b>Silver 3/3</b></h5><hr> | ||
Line 29: | Line 29: | ||
<li><b>Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected</b><br> | <li><b>Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected</b><br> | ||
Our new devices <a target="blank" href="http://parts.igem.org/Part:BBa_K2018014">K2018014</a> and <a target="blank" href="http://parts.igem.org/Part:BBa_K2018015">K2018015</a>, hybrid bacteriocins, has shown great effect at inhibit growth of multi-resistant Staphylococcus aureus and Pseudomonas aeruginosa. The hybrids showed greater effect than the single bacteriocin proteins, this suggests that the two bacteriocins in the hybrid has a synergistic effect. | Our new devices <a target="blank" href="http://parts.igem.org/Part:BBa_K2018014">K2018014</a> and <a target="blank" href="http://parts.igem.org/Part:BBa_K2018015">K2018015</a>, hybrid bacteriocins, has shown great effect at inhibit growth of multi-resistant Staphylococcus aureus and Pseudomonas aeruginosa. The hybrids showed greater effect than the single bacteriocin proteins, this suggests that the two bacteriocins in the hybrid has a synergistic effect. | ||
− | + | </li> | |
<li><b>Collaboration</b><br> | <li><b>Collaboration</b><br> | ||
We have helped these iGEM teams in different ways: The iGEM team from the Technical University of Denmark, the iGEM team from Copenhagen University, the iGEM team from Chalmers University of Technology, the iGEM team from Stockholm, the iGEM team from Virginia and the iGEM team from LMU TUM munich. For more details see <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Collaborations">here</a>. </li> | We have helped these iGEM teams in different ways: The iGEM team from the Technical University of Denmark, the iGEM team from Copenhagen University, the iGEM team from Chalmers University of Technology, the iGEM team from Stockholm, the iGEM team from Virginia and the iGEM team from LMU TUM munich. For more details see <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Collaborations">here</a>. </li> | ||
Line 40: | Line 40: | ||
By talking with experts in the areas of therapeutic use of biodegradable plastic, and an expert in the use antibiotics and how bacteriocins can be an useful element in the fight against antibiotic resistance. Furthermore we made a survey with one of the high schools we visited and used their feedback to improve message. At last we made a survey with danish companies that work with plastic in production and the possible interest in the use of plastic made by bacteria for more information go to <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Integrated_Practices">Integrated Human Practice</a>.</li> | By talking with experts in the areas of therapeutic use of biodegradable plastic, and an expert in the use antibiotics and how bacteriocins can be an useful element in the fight against antibiotic resistance. Furthermore we made a survey with one of the high schools we visited and used their feedback to improve message. At last we made a survey with danish companies that work with plastic in production and the possible interest in the use of plastic made by bacteria for more information go to <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Integrated_Practices">Integrated Human Practice</a>.</li> | ||
<li><b>Improve the function OR characterization of an existing BioBrick Part or Device and enter this information in the Registry</b><br> | <li><b>Improve the function OR characterization of an existing BioBrick Part or Device and enter this information in the Registry</b><br> | ||
− | + | We've done characterization of the hybrid promoter phaCAB biobrick created by imperial colleges iGEM team in 2012. They documented that this biobrick generated 11 times as much plastic as the original phaCAB created by tokyo tech. By creating a small library of </li> | |
<li><b>Demonstrate a functional proof of concept of your project show your project working under real-world conditions. Your proof of concept must consist of a BioBrick device; a single BioBrick part cannot constitute a proof of concept</b><br> | <li><b>Demonstrate a functional proof of concept of your project show your project working under real-world conditions. Your proof of concept must consist of a BioBrick device; a single BioBrick part cannot constitute a proof of concept</b><br> | ||
By producing bacteriocins and PHB from different biobrick devices we have demonstrated a <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Proof">functional proof of concept</a>. Furthermore we have biobrick device which can secrete PHB.</li> | By producing bacteriocins and PHB from different biobrick devices we have demonstrated a <a target="blank" href="https://2016.igem.org/Team:SDU-Denmark/Proof">functional proof of concept</a>. Furthermore we have biobrick device which can secrete PHB.</li> |
Revision as of 17:18, 10 October 2016
Achievements
Bronze 4/4
- Register for iGEM, have a great summer, and attend the Giant Jamboree
We registered and was accepted by iGEM Headquarters on 2016-05-10 09:08:56 we definitely had a great summer, and we are excited to attend at the Giant Jamboree. - Meet all deliverables on the Requirements page
We sure did, you are reading the wiki right now.
We are looking forward to attend the Giant Jamboree in Boston, where we will present our project with a talk and a poster.
We registered and submitted all the parts we have made.
We filled out the the safety forms and judging forms as the HQ asked. - Clearly attribute each aspect of the project
In the section of attribution, we described all the help we have acknowledged. - Document at least one new standard BioBrick Part or Device central to your project and submit this part to the iGEM Registry.
K2018030 is a secretion system for poly-beta-hydroxybutyrate (PHB). This secretion tags PHB with a hybrid protein consisting of phasin, a protein that binds PHB, and a hemolysin tag, that is recognised by a type 2 secretion system. The biobrick also contains two transport proteins that will recognize the hybrid protein, and secrete it along with PHB. This construct generates an enormous increase in PHB yield, and creates the possibility for a large scale continous production of PHB in a fed batch.
Silver 3/3
- Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected
Our new devices K2018014 and K2018015, hybrid bacteriocins, has shown great effect at inhibit growth of multi-resistant Staphylococcus aureus and Pseudomonas aeruginosa. The hybrids showed greater effect than the single bacteriocin proteins, this suggests that the two bacteriocins in the hybrid has a synergistic effect. - Collaboration
We have helped these iGEM teams in different ways: The iGEM team from the Technical University of Denmark, the iGEM team from Copenhagen University, the iGEM team from Chalmers University of Technology, the iGEM team from Stockholm, the iGEM team from Virginia and the iGEM team from LMU TUM munich. For more details see here. - Human practice
We presented at different events and discussed synthetic biology. We were in laboratory with high schoolers, we made two short movies about our project and iGEM for more information read the chapter on Practices and Prospects.
Gold 4/4
- Integrated human practice, Expand on your silver medal activity of human practice by demonstrating how you have integrated the investigated issues into the design and/or execution of your project
By talking with experts in the areas of therapeutic use of biodegradable plastic, and an expert in the use antibiotics and how bacteriocins can be an useful element in the fight against antibiotic resistance. Furthermore we made a survey with one of the high schools we visited and used their feedback to improve message. At last we made a survey with danish companies that work with plastic in production and the possible interest in the use of plastic made by bacteria for more information go to Integrated Human Practice. - Improve the function OR characterization of an existing BioBrick Part or Device and enter this information in the Registry
We've done characterization of the hybrid promoter phaCAB biobrick created by imperial colleges iGEM team in 2012. They documented that this biobrick generated 11 times as much plastic as the original phaCAB created by tokyo tech. By creating a small library of - Demonstrate a functional proof of concept of your project show your project working under real-world conditions. Your proof of concept must consist of a BioBrick device; a single BioBrick part cannot constitute a proof of concept
By producing bacteriocins and PHB from different biobrick devices we have demonstrated a functional proof of concept. Furthermore we have biobrick device which can secrete PHB. - Show your project working under real-world conditions. To achieve this criterion, you should demonstrate your whole system, or a functional proof of concept working under simulated conditions in the lab
By making MIC’s with our bacteriocins in the lab hereby we have shown that they work against different human pathogens, and can therefore be used in real-world conditions. By 3D printing actually products by our produced PHB we have demonstrated our whole systems works under real-world conditions and can be used, furthermore the coding of PHB as a drug delivery to see more go to results and proof of concept.